Zobrazeno 1 - 10
of 50
pro vyhledávání: '"BO E. HEDLUND"'
Autor:
Fernando Ferreira Costa, Wilson A. Ferreira, Juliete A.F. Silva, Erica M.F. Gotardo, Nicola Conran, Hanan Chweih, Lediana I. Miguel, Flavia C. Leonardo, Howard L. Elford, Bo E. Hedlund
Publikováno v:
Blood Cells, Molecules, and Diseases. 81:102404
Autor:
Bo E. Hedlund, Philip E. Hallaway
Publikováno v:
Iron and Human Disease ISBN: 9781351073899
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41ee36c2280432e72f17bacb6d06804d
https://doi.org/10.1201/9781351073899-21
https://doi.org/10.1201/9781351073899-21
Autor:
Howard L. Elford, Devashish Joshi, Christopher R. Chitambar, Mona M. Al-Gizawiy, Bo E. Hedlund, Kathleen M. Schmainda, Hisham S. Alhajala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0990b55936f3b05662652d5bb1f2d32c
https://europepmc.org/articles/PMC5692060/
https://europepmc.org/articles/PMC5692060/
Autor:
Robert P. Hebbel, Bo E. Hedlund
Publikováno v:
American journal of hematology. 93(3)
Autor:
Juliete A.F. Silva, Nicola Conran, Howard L. Elford, Erica M.F. Gotardo, Flavia C. Leonardo, Wilson A. Ferreira, Lediana I. Miguel, Bo E. Hedlund, Hanan Chweih, Fernando Ferreira Costa
Publikováno v:
Blood. 132:1034-1034
Introduction: Several diseases and disorders, including hereditary and acquired hemolytic anemia, blood transfusion reactions, preeclampsia and some infections, incur intravascular hemolysis to varying degrees. The destruction of red blood cells and
Autor:
Bo E. Hedlund, Elliott Vichinsky, Paul R. Dragsten, Robert W. Grady, Patricia J. Giardina, Michael Jeng, Jacqueline Madden, Paul Harmatz, Becky Miller, Hanson Gregory J
Publikováno v:
British Journal of Haematology. 138:374-381
The most widely used drug for iron chelation is deferoxamine (DFO) mesylate. While effective in promoting iron excretion, it requires prolonged daily infusions, often resulting in poor compliance. A clinical trial was conducted using starch-conjugate
Autor:
Mark S. Paller, Bo E. Hedlund
Publikováno v:
Free Radical Biology and Medicine. 17:597-603
Iron is an important contributor to reoxygenation injury because of its ability to promote hydroxyl radical formation. In previous in vivo studies, we demonstrated that iron chelators that underwent glomerular filtration provided significant protecti
Autor:
Donald W. Pettigrew, Benjamin W. Turner, Winston F. Moo-Penn, Francine R. Smith, Bo E. Hedlund, Michael L. Doyle, George J. Turner, Gary K. Ackers, Frederic Galacteros, Donald L. Rucknagel
Publikováno v:
Proteins: Structure, Function, and Genetics. 14:333-350
Free energies of oxygen-linked subunit assembly and cooperative interaction have been determined for 34 molecular species of human hemoglobin, which differ by amino acid alterations as a result of mutation or chemical modification at specific sites.
Publikováno v:
Journal of Cardiovascular Pharmacology. 16:523-528
Iron catalyzes reactions during ischemia and reperfusion that contribute to myocardial injury. The iron-chelator deferoxamine blocks these reactions, but undesirable side effects limit the clinical potential of deferoxamine to decrease injury. We tes
Autor:
Mark B. Landon, Janice J. Ophoven, Robert L. Schmidt, John A. Widness, Bo E. Hedlund, Anne E. Faassen, Marla M. Mills, Michael K. Georgieff
Publikováno v:
The Journal of Pediatrics. 117:455-461
Because chronic hypoxemia causes a redistribution of iron from serum and storage pools into an expanding erythrocyte mass, and because infants of diabetic mothers are often hypoxemic in utero and have a high prevalence of polycythemia at birth, we st